Editor's Note: The following is a BioMed Realty Trust announce.
BioMed Realty Trust, Inc. (NYSE: BMR) today announced the appointment of Dr. William R. Brody, President of the Salk Institute for Biological Studies, to its board of directors, increasing the board to nine members.
"It is with great pleasure that we welcome Dr. Brody to our board," said Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty. "He is recognized internationally for his accomplishments in biomedical engineering, including over 100 publications and two U.S. patents in the field of medical imaging, and currently serves in numerous leadership positions at some of the world's most prestigious corporate, medical research, educational and government institutions."
Dr. Brody received his B.S. and M.S. degrees in electrical engineering from the Massachusetts Institute of Technology, and his M.D. and Ph.D. (also in electrical engineering) from Stanford University where he served as an associate professor and then professor of radiology and electrical engineering. He has been a co-founder of three medical device companies, and served as the president and chief executive officer of Resonex Inc.
Mr. Gold added, "Adding Dr. Brody to our highly accomplished board brings a depth and breadth of expertise in life science – and specifically in neuroscience, genetics and cell biology – that, along with our focus on cultivating valuable relationships, will continue to distinguish BioMed Realty as the leader in life science real estate."
Dr. Brody has served as president of the Salk Institute for Biological Studies since March 2009, one of the world's preeminent research institutions studying neuroscience, genetics and cell and plant biology to gain better understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases. He previously served as president of The Johns Hopkins University from 1996 to 2009.
Dr. Brody currently serves on the board of directors and corporate governance committee of International Business Machines Corp., and on the board of directors and compensation committee of Novartis AG. He is also an independent director and trustee for funds of T. Rowe Price and a member of the board of trustees of Stanford University.